Behind the Push to Keep Higher-Priced EpiPen in Consumers' Hands

More than seven months after the introduction of a generic version of the allergy drug, the more expensive brand-name EpiPen still accounts for over a quarter of the market. One reason is that a middleman can profit from the sale of such pricier medicines.

from WSJ.com: US Business http://ift.tt/2hzbOLJ
via IFTTT